New Drug Cuts Rare Disease Triglycerides by 32%

People living with a rare genetic disorder that causes dangerously high fat levels in their blood now have a new weapon in their medical arsenal.

The UK's Medicines and Healthcare products Regulatory Agency approved olezarsen (brand name Tryngolza) on April 10, 2026, for adults with familial chylomicronemia syndrome. This inherited condition prevents the body from properly breaking down fats, leading to triglyceride levels so high they can trigger acute pancreatitis, a painful and potentially deadly inflammation of the pancreas.

For patients with FCS, life often means strict dietary restrictions and constant fear of the next emergency. Recurring bouts of severe abdominal pain can lead to long-term organ damage and life-threatening complications.

The approval came after a clinical study of 66 adults with the condition showed remarkable results. Half received the new treatment alongside a controlled low-fat diet, while the other half got a placebo.

After six months, patients taking olezarsen saw their triglyceride levels drop by an average of 32%. The placebo group, meanwhile, experienced a 12% increase in these dangerous fat levels.

The benefits didn't stop there. Patients continued treatment for a full year and saw their improvements maintained and even enhanced over time.

The Ripple Effect

Perhaps most importantly, people taking the medication experienced fewer cases of acute pancreatitis, the most feared complication of FCS. For patients who've spent years or decades managing emergency hospital visits and chronic pain, this reduction represents a tangible improvement in daily quality of life.

Julian Beach, MHRA's Interim Executive Director of Healthcare Quality and Access, emphasized the significance for this underserved patient population. Treatment options for FCS have historically been extremely limited, leaving many people with few choices beyond restrictive diets.

The regulatory agency will continue monitoring the drug's safety and effectiveness as more patients access it. This ongoing surveillance ensures that any concerns can be addressed quickly while helping more people benefit from the treatment.

For families affected by this rare condition, the approval represents years of hope finally realized through scientific progress and clinical evidence.